Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options-Reference-Cited by-同舟云学术

Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options

Published:2019-08 Issue:10199 Volume:394 Page:697-708
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ray Kausik K,Corral Pablo,Morales Enrique,Nicholls Stephen J

Publisher

Elsevier BV

Subject

General Medicine

Reference101 articles.

1. Clofibrate and niacin in coronary heart disease;Stamler;JAMA,1975

2. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin;Canner;J Am Coll Cardiol,1986

3. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia;Frick;N Engl J Med,1987

4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);Lancet,1994

5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group;Shepherd;N Engl J Med,1995

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to prevent or reduce inequalities in specific avoidable causes of death for adults with intellectual disability: A systematic review;British Journal of Learning Disabilities;2024-01-31

2. Dyslipidemia;Hypertension;2024

3. Therapeutic opportunities for the treatment of NASH with genetically validated targets;Journal of Hepatology;2023-10

4. A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates;npj Vaccines;2023-09-28

5. Fixed Combination for the Treatment of Dyslipidaemia;Current Atherosclerosis Reports;2023-09-16